Moreover, activation of RUNX2 by AKT has more impact and was better investigated in prostate cancer than in breast cancer since prostate cancer mainly causes osteoblastic lesions, and RUNX2 depicts a pro-osteogenic transcription factor. The gene discussed is AKT1; the disease is breast carcinoma.